Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00207116
First received: September 12, 2005
Last updated: October 26, 2015
Last verified: October 2015
  Purpose
The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer

Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Drug: Cetuximab
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Prediction of response to Erbitux with non small cell lung cancer

Secondary Outcome Measures:
  • Radiographic Response

Estimated Enrollment: 120
Study Start Date: September 2005
Study Completion Date: March 2006
Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: Cetuximab
IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.
Other Name: Erbitux

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Measurable disease tumor available for biopsies
  • Life expectancy of at least 3 months

Exclusion Criteria:

  • Known or documented brain metastases prior to Cetuximab therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00207116

Locations
United States, Delaware
Local Institution
Newark, Delaware, United States
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

Additional Information:
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT00207116     History of Changes
Obsolete Identifiers: NCT00118118
Other Study ID Numbers: CA225-065 
Study First Received: September 12, 2005
Last Updated: October 26, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Eli Lilly and Company:
Metastatic Non Small Cell Lung Cancer

Additional relevant MeSH terms:
Carcinoma
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Neoplastic Processes
Pathologic Processes
Cetuximab
Antineoplastic Agents

ClinicalTrials.gov processed this record on September 27, 2016